CAHAN Health Update: Distribution and Patient Prioritization for Tixagevimab/Cilgavimab (Evusheld) February 18, 2022 anti-SARS-CoV-2, CAHAN, California Department of Public Health, CDPH, cilgavimab, COVID-19, Evusheld, high-risk outpatients, immune response, LAC DPH, LAHAN, Los Angeles, Los Angeles County, monoclonal antibody, NIH, prophylaxis, therapeutics, tixagevimab 1154 The California Department of Public Health (CDPH) issued a CAHAN on the distribution and patient prioritization for tixagevimab/cilgavimab (Evusheld). Evusheld is an anti-SARS-CoV-2 spike monoclonal antibody authorized for pre-exposure prophylaxis of COVID-19. It is intended to protect individuals who are unable to mount an adequate immune response to COVID-19 vaccination or are unable to receive a COVID-19 vaccine due to a history of a severe adverse reaction. The CAHAN includes suggested patient prioritization based on NIH guidance should supplies of this product become limited. LAC DPH also recommends that providers consider patients living in under resourced communities (healthyplacesindex.org) in developing their patient prioritizations for Evusheld. Healthcare providers in LA County are encouraged to visit the LAC DPH Monoclonal & Antiviral Therapy for Non-Hospitalized Patients website to learn more about currently available therapeutics and how to procure and prescribe medication for their high-risk outpatients. Facilities that are interested in becoming an Evusheld provider or that have other therapeutics related questions can contact LAC DPH at DPH-Therapeutics@ph.lacounty.gov. The full CDPH communication can be viewed here. To view a printable PDF of this communication and other LAHAN communications, please visit publichealth.lacounty.gov/lahan. If this message was forwarded to you, please join LAHAN here.